Categories: HealthcareNews

Agile Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on Monday, November 7, 2022

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Live Conference Call and Webcast at 4:30 p.m. ET

PRINCETON, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced it will report third quarter 2022 financial results after the market close on Monday, November 7, 2022. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss the Company’s financial results and provide a business update.

Event Agile Therapeutics Third Quarter 2022 Financial Results Conference Call
Date Monday, November 7, 2022
Time 4:30 p.m. ET / 1:30 p.m. PT

A live webcast of the conference call may be accessed via the Investor Relations portion of the Agile Therapeutics website at https://ir.agiletherapeutics.com/events-and-presentations. To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call.

About Agile Therapeutics, Inc.
Agile Therapeutics is a women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website, Twitter account (@agilether), and LinkedIn account. 

CONTACT: Contact:
Matt Riley
Head of Investor Relations & Corporate Communications
mriley@agiletherapeutics.com

Staff

Recent Posts

NUTEX HEALTH ANNOUNCES INTERNET AVAILABILITY OF PROXY MATERIALS FOR ITS 2025 ANNUAL MEETING

HOUSTON, June 2, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:…

5 hours ago

Sony, SCREEN, and VitroVo to Start Trial Offer of MEA System Capable of Simultaneous Measuring and Recording Data from Approximately 237,000 Electrodes

Contributing to high-definition visualization of cellular activity and supporting research into neuronal and cardiac diseases…

5 hours ago

PAIG AI Rebrands as Trust3 AI to Lead the Way in Trusted AI Adoption

SAN FRANCISCO, June 2, 2025 /PRNewswire/ -- PAIG AI, a leading provider of AI governance…

5 hours ago

Delivra Health Brands, and Its Dream Water(R) Brand, Partners with QVC to Bring Dream Water to Online Shoppers Across the US

Vancouver, British Columbia--(Newsfile Corp. - June 2, 2025) - Delivra Health Brands Inc. (TSXV: DHB) (OTCQB:…

12 hours ago

Medicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering

Philadelphia, Pennsylvania--(Newsfile Corp. - June 2, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company")…

15 hours ago

Hologic Joins NEST Governance Committee to Advance the Use of Real-World Data in Medical Device Evaluation

ARLINGTON, Va.--(BUSINESS WIRE)--The National Evaluation System for health Technology (NEST), an initiative of the Medical…

17 hours ago